Navigation Links
Biomoda and Averion International Announce Agreement for Clinical Services
Date:10/4/2007

ALBUQUERQUE, N.M., Oct. 4 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today an agreement with Averion International Corporation of Southborough, Mass. to provide a range of clinical services including protocol design and study implementation for Biomoda's clinical programs.

"Averion is a global clinical research organization that offers the broad range of services required of a company like Biomoda that is looking to enter the world market," said John Cousins, President of Biomoda. "As a clinical research organization, Averion can rapidly deliver world-class study design, protocol development and clinical trial implementation. Equally important, Averion has the most enviable track record for FDA approvals in the industry."

Averion (http://www.averionintl.com) is a leading Clinical Research Organization (CRO) with a heritage and depth in pharmaceutical, biotechnology, and medical devise trials across a wide range of indications. It is a globally preeminent CRO with a focus in oncology, dermatology, nephrology, and medical devices and offers comprehensive understanding of what it takes to efficiently manage clinical trials from Phase I-IV through to post-marketing studies, safety surveillance and patient registries.

Biomoda's technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

Contact: John Cousins

(505) 821-0875


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. International community warns India on HIV situation
2. Key step forward on International Health Rules
3. ICMR along with other International Research organisation with drug development for Neglected Diseases
4. International Osteoporosis Research Centre To Be Started In India.
5. Indian hospitals require International Accreditation
6. International Conference On Malaria - Laveran To Genomics
7. Delhi To Host International Women’s Congress From Nov 2
8. International conference on Ayurveda to be held on Kerala
9. International Teleradiology: The Future Of Radiologic Diagnosis
10. International Rating System To Be Introduced For Hospitals In India
11. John Mendelsohn M.D, chosen for an International Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology: